%0 Journal Article %A DIRK RADES %A JASPAR WITTELER %A STEVEN E. SCHILD %A PETER TRILLENBERG %A MATTEO M. BONSANTO %A JAN LEPPERT %T A New Survival Score for Patients Receiving Radiotherapy for Newly Diagnosed Glioblastoma Multiforme %D 2021 %R 10.21873/anticanres.14786 %J Anticancer Research %P 379-384 %V 41 %N 1 %X Background/Aim: In a previous study investigating radiotherapy for newly diagnosed glioblastoma multiforme (GBM), significant or almost significant associations with survival were found for performance status, upfront resection, O6-methylguanine-DNA methyl-transferase (MGMT) promoter methylation and unifocal GBM. This study aimed to create a survival score based on these factors. Patients and Methods: Most of the 81 patients included received resection of GBM followed by radiochemotherapy (59.4 Gy/33 or 60 Gy/30 fractions). The previously identified predictors of survival were re-evaluated. Factors significantly associated with survival were used for the score. Results: All factors were significantly associated with survival. For each factor, 0 points (less favorable survival) or 1 point (more favorable survival) were assigned and added for each patient. Three groups were designed, 0-1 (n=10), 2 (n=21) and 3-4 points (n=50); 12-month survival rates were 0%, 38% and 78% (p<0.001). Conclusion: A new survival score was created for patients requiring radiotherapy for GBM that can improve treatment personalization. %U https://ar.iiarjournals.org/content/anticanres/41/1/379.full.pdf